Home Compare HOLX vs PFE
Stock Comparison · Structural lead, mixed market

Hologic vs Pfizer: Which Stock Looks Stronger in 2026?

Hologic holds the cleaner structural position, with the lead spread across profitability and stability. Pfizer still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both profitability and stability materially support the lead. Hologic, Inc. leads by 28 points on the overall comparison score.

Trajectory Similarity
0.59
Moderately similar
Peer-set rank: #32
within Hologic, Inc.'s functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The strongest overlap appears in recent revenue growth and margin trend.

Similarity drivers
recent revenue growthmargin trend
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
HOLX
Hologic, Inc.
70
Peer-Score
Signal qualityHigh
vs
PFE
Pfizer Inc.
42
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: HOLX vs PFE Profitability 75 12 Stability 90 48 Valuation 67 82 Growth 46 19 HOLX PFE
Gap Ranking
#1 Profitability +63
#2 Stability +42
#3 Growth +27
#4 Valuation +15
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for HOLX and PFE Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer HOLXPFE Relative valuation Structural strength

Structure clearly favours Hologic, Inc., even though current pricing leans the other way.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
On profitability, Hologic, Inc. ranks near the top of the group; Pfizer Inc. sits in the weaker half.
Stability
On stability, the same pattern holds: both are strong, but Hologic, Inc. still leads clearly.
Profitability — Dominant Gap
HOLX
75
PFE
12
Gap+63in favour of HOLX

Capital efficiency adds support, with a 4.8-point ROIC advantage.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Pfizer, with a forward P/E that is 6 turns lower there.

What this means for the comparison

The lead is built on both profitability and stability — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the HOLX vs PFE comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-stability comparisons

Explore how HOLX and PFE each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.